000			03249nam a22003855i 4500
001			106831
003			ESmaUEC
005			20240119142143.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			190110s2018 gw | s |||| 0|eng d
020			_a9783030105075 _9
024	7		_a10.1007/978-3-030-10507-5 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC
050		4	_aRC271.C5 _b2018 EB
245	0	0	_aMechanisms of Drug Resistance in Cancer Therapy _cedited by Mario Mandalà, Emanuela Romano
264		1	_aCham _bSpringer International Publishing _c2018
300			_a1 recurso en línea (VIII, 297 páginas) _b32 ilustraciones, 31 ilustraciones a color
336			_aTexto _btxt _2rdacontent
347			_atext file _bPDF _2rda
490	0		_aHandbook of Experimental Pharmacology _x0171-2004 _v249
505	0		_a1. Molecular and Pharmacological Mechanisms of Drug Resistance: An Evolving Paradigm -- 2. Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival -- 3. Immune-Mediated and Hypoxia-Regulated Programs: Accomplices in Resistance to Anti-angiogenic Therapies -- 4. Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer -- 5. Mechanisms of Drug Resistance in Melanoma -- 6. Mechanisms of Resistance to Immune Checkpoint Antibodies -- 7. Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma -- 8. Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer -- 9. Targeting DNA repair -- 10. Resistance to Hormonal Therapy in Prostate Cancer -- 11. Mechanism of Resistance in Gastrointestinal Stromal Tumors -- 12. Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia -- 13. Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia -- 14. Mechanisms of Resistance in Multiple Myeloma -- 15. Cancer Evolution as the New Frontier of Precision.
520	3		_aA major objective of this book is to reveal unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive and prognostic biomarkers to enable patient stratification and tailor treatments. It offers to the readers an updated overview on the possible reasons of failure of new and promising therapeutic opportunities.
650		4	_aCáncer _xQuimioterapia _9674463
700	1		_aMandalà, Mario _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aRomano, Emanuela _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _1http://viaf.org/viaf/148105729 _9106996
776	0	8	_iPrinted edition: _z9783030105068
776	0	8	_iPrinted edition: _z9783030105082
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-10507-5 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
490	0		_aBiomedical and Life Sciences (Springer-11642)
942			_2lcc
988			_aEBSPRINGER_BIOMEDLIFE_2019
998			_aSI _a_alco _a_vill _b01/2019 _cm _dz _ef _feng _ggw _h0
999			_c106831 _d106831 _x1